This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
The European Commission has cleared the acquisition of Hospira by Pfizer in phase 1. The clearance is subject to the divestment of some sterile injectable drugs and one biosimilar pipeline.
A CRA team advised and provided economic support to Pfizer during the pre-notification and phase 1 proceedings in front of the European Commission.
For more details, please see the Commission’s press release.
Svend Albaek and Raphaël De Coninck explore the proposed use of “dynamic capabilities” analysis in European merger control as authorities increasingly focus on...
Under these circumstances, it is however not entirely clear how the future competitive landscape will look like, merger effects cannot be modelled with a high...
Oli Latham is a panelist during the session discussing “Power, AI and Ecosystems.” For more information on this event, click here.
Oli Latham is a panelist on “Discussing the Evolving Interplay Between Competition Law and Consumer Protection” and will discuss the: Intersection of...
